GlaxoSmithKline

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Global X Robotics & Artificial Intelligence ETF

iShares U.S. Healthcare Providers ETF

Teladoc

Utilities Select Sector SPDR Fund

Although broader markets may continue to be volatilie in the rest of the year, these five hot stocks to buy should be on your shopping list.
The post 5 Hot Stocks to Buy Still Profiting From Social Distancing appeared first on InvestorPlace.

5 Hot Stocks to Buy Still Profiting From Social Distancing

AbbVie

Amgen

Gilead Sciences

Johnson & Johnson

Merck

Novartis

Pfizer

Roche Holding AG

Sanofi

As evidence grew this spring that the drug remdesivir was helping COVID-19 patients, some Wall Street investors bet on analysts’ estimates that its maker, Gilead Sciences Inc , could charge up to $10,000 for the treatment.

Big Pharma wages stealth war on drug price watchdog

Innoviva

With the approval for the asthma indication, Glaxo's (GSK) Trelegy becomes the first single inhaler triple therapy approved for the maintenance treatment of both asthma and COPD.

Glaxo/Innoviva's Trelegy Ellipta Gets FDA Nod for Asthma

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) announced the US Food and Drug Administration (FDA) has approved a new indication for Trelegy Ellipta (fluticasone furoate / umeclidinium / vilanterol ‘FF/UMEC/VI’) for the treatment of asthma in patients aged 18 years and older adding to its current license for use in patients with chronic obstructive pulmonary disease (COPD). Trelegy Ellipta is not indicated for relief of acute bronchospasm.

FDA Approves Trelegy Ellipta as the First Once-Daily Single Inhaler Triple Therapy for the Treatment of Both Asthma and COPD in the US

AstraZeneca

BioNTech SE

Moderna

Novavax

The COVID-19 vaccine developers pledge to observe high ethical standards and sound scientific principles in conducting clinical studies and manufacturing of vaccines.

CEOs of Nine Coronavirus Vaccine Makers Sign Safety Pledge

These healthcare companies have had plenty of help in building the manufacturing capacity needed to produce billions of vaccine doses.

6 Companies Racing to Mass-Produce a Coronavirus Vaccine in 2021

WARREN, N.J., Sept. 8, 2020 /PRNewswire/ -- GSK Consumer Healthcare (LSE/NYSE: GSK) today announced the launch of new Advil Dual Action, an exclusive formula that combines two of the most powerful pain fighting ingredients: ibuprofen and acetaminophen.

GSK Consumer Healthcare Introduces the Biggest Innovation in the U.S. Over-The-Counter Oral Pain Relief Category in 25 Years: New Advil Dual Action with Acetaminophen

Nine leading U.S. and European vaccine developers pledged to uphold the scientific standards that their experimental immunizations will be held against, amid a hurried global race to contain the pandemic.

Nine biopharma CEOs pledge to make safety the main focus in coronavirus vaccine development

Diageo

eBay

General Mills

H&R Block

Hormel Foods

Kimberly-Clark

Lockheed Martin

Lam Research

PepsiCo

Philip Morris

Unilever

33 Dividend Stocks Fit For COVID-19 Times: A September Update

A quick approval would be nice, but the drugmakers are sticking to their scientific principals.

Moderna, Pfizer, Johnson & Johnson, And Others To Make Pledge in Response to Coronavirus Vaccine Political Pressure

With competitors already in phase 3 development, the European drugmakers are just now starting a phase 1/2 clinical trial.

Better Late Than Never: Sanofi and GlaxoSmithKline Start Coronavirus Vaccine Clinical Trial Program

Sanofi (SNY) and Glaxo have a collaboration to develop an adjuvant vaccine against coronavirus.

Sanofi, Glaxo Start Clinical Study on Coronavirus Vaccine

Novavax and the team of Sanofi and GlaxoSmithKline separately reported trial advances with their Covid vaccine candidates, sending shares of NVAX and SNY rising in early trading Thursday.
The post Novavax Posts Good Covid Vaccine Data; Sanofi, GlaxoSmithKline Start First Human Tests appeared first on Investor's Business Daily.

Novavax Posts Good Covid Vaccine Data; Sanofi, GlaxoSmithKline Start First Human Tests

Shares of Sanofi SNY, +1.06% SAN, +0.97% gained 0.4% in premarket trading on Thursday after the drugmaker and GlaxoSmithKline GSK, +2.41% said their COVID-19 vaccine candidate has entered a Phase 1/2 clinical trial.

Sanofi, GSK's coronavirus vaccine candidate enters clinical trials

Sanofi SA (NASDAQ: SNY) and GlaxoSmithKline PLC (NYSE: GSK) on Thursday announced they had started the early-stage clincial trials for for their COVID-19 vaccine candidate the same day.

Sanofi, GSK Start Early-Stage Clinical Trials Of Jointly-Developed COVID-19 Vaccine

Sanofi and GSK initiate Phase 1/2 clinical trial of COVID-19 adjuvanted recombinant protein-based vaccine candidate

Glaxo (GSK) and Vir Biotechnology have a collaboration to develop antibody therapies for treating COVID-19.

Glaxo/Vir Biotech Begin Clinical Study on Coronavirus Therapy

Vir Biotechnology

The treatment to prevent hospitalization from COVID-19 could be available in the first half of 2021.

Vir Biotechnology and GSK Launch Phase 2/3 Study of COVID-19 Antibody

Media reports of the U.S. Food and Drug Administration looking to approve a coronavirus vaccine prior to the completion of clinical trials appear to be taken out of context, former FDA Commissioner Dr.

COVID-19 Update: Gottlieb On Vaccine Approval Timeline, GSK Exec Talks Antibody Drug

Abbott Labs

Market Waits for Major Economic Data This Week.

Market Waits for Major Economic Data This Week

Shares of Vir Biotechnology Inc. VIR, +1.31% gained 9.2% in premarket trading on Monday when the company and GlaxoSmithKline GSK, -0.37% said they had begun dosing patients in the Phase 2/3 clinical study for their experimental COVID-19 antibody treatment.

Vir and GSK start Phase 2/3 trial for experimental COVID-19 treatment

GlaxoSmithKline and partner Vir Biotechnology have started testing their experimental antibody on early-stage Covid-19 patients.

GlaxoSmithKline and partner Vir join the race to find a coronavirus antibody treatment

GlaxoSmithKline and partner Vir Biotechnology have started testing their experimental antibody on early-stage COVID-19 patients, entering the race to find a winner in a promising class of antiviral drugs to combat the pandemic.

GSK, partner Vir join race to find COVID-19 antibody treatment

SAN FRANCISCO and LONDON, Aug.  31, 2020  (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) announced that the first patient was dosed last week in a Phase 2/3 study with VIR-7831 (also known as GSK4182136), a fully human anti-SARS-CoV-2 (Severe Acute Respiratory Syndrome coronavirus-2) monoclonal antibody, for the early treatment of COVID-19 in patients who are at high risk of hospitalization.

News for GlaxoSmithKline Stock (GSK)